MoFo News Item

MoFo Advises Evolve BioSystems in Series D Financing

23 Feb 2021

Morrison & Foerster advised Evolve BioSystems Inc. in its $55 million Series D financing co-led by Cargill Inc., a global food, agricultural, financial, and industrial products company, and Manna Tree Partners, an investment firm committed to improving human health. The new capital will be used to help the company continue commercializing a next generation of probiotic capable of addressing a widespread deficiency in the infant gut microbiome.

Based in Davis, California, Evolve manufactures and distributes Evivo, a proprietary groundbreaking probiotic proven to resolve infant gut dysbiosis, or Newborn Gut Deficiency. Evivo is comprised of activated B. infantis EVC001, which studies have shown guides critical development of infants’ digestive and immune systems. Evivo restores this missing bacterium to the infant gut microbiome, reducing potentially pathogenic bacteria by 80 percent, as well as significantly reducing intestinal inflammation. Evolve was spun off from the Foods for Health Institute at the University of California, Davis in 2014, and MoFo has advised the company from near inception.

The MoFo deal team was led by John Campbell, senior counsel in the firm’s Emerging Companies + Venture Capital Group, and included corporate associates Kate Tyler and Connor Acle, all based in San Francisco.

Read more about the transaction in the company's press release.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.